Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI

BEVERLY, MA–(Marketwired – Mar 31, 2014)- Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company’s clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).  One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.

The trial compares three different dosing regimens of Brilacidin, two single-dose regimens and one 3-day regimen, to a standard 7-day regimen of daptomycin, a drug marketed in the United States by Cubist Pharmaceuticals under the brand name Cubicin.  

“The shortest dosing regimen of any antibiotic treatment for ABSSSI approved by the U.S. Food and Drug Administration is seven days,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix.  “We believe that among comparably priced drugs that are safe and effective, the shortest course regimen will take over the market.  We are pleased that the trial of our one- and three-day Brilacidin treatment is on schedule to date and we anticipate enrollment to be 50 percent complete in another six weeks.”